Moore Mary Courtney, DiCostanzo Catherine A, Dardevet Dominique, Lautz Margaret, Farmer Ben, Neal Doss W, Cherrington Alan D
Dept. of Molecular Physiology & Biophysics, 702 Light Hall, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, USA.
Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1057-63. doi: 10.1152/ajpendo.00313.2004. Epub 2004 Aug 17.
Intraportal delivery of serotonin enhanced net hepatic glucose uptake (NHGU) during a hyperinsulinemic hyperglycemic clamp, but serotonin elevated catecholamines and can cause gastrointestinal distress. We hypothesized that the selective serotonin reuptake inhibitor (SSRI) fluvoxamine would enhance NHGU without side effects. Arteriovenous difference and tracer ([3-(3)H]glucose) techniques were used in conscious 42-h-fasted dogs. Experiments consisted of equilibration (-120 to -30 min), basal (-30 to 0 min), and experimental (EXP; 0-270 min) periods. During EXP, somatostatin, fourfold basal intraportal insulin, basal intraportal glucagon, and peripheral glucose (to double the hepatic glucose load) were infused. Saline (SAL) was infused intraportally during 0-90 min (P1), and fluvoxamine was infused intraportally at 0.5, 1, and 2 mug.kg(-1).min(-1) from 90 to 150 (P2), 150 to 210 (P3), and 210 to 270 (P4) min, respectively, in the FLUV group (n = 8). The SAL group (n = 9) received intraportal saline during 0-270 min. NHGU in SAL was 13.9 +/- 1.7 and 17.0 +/- 2.0 mumol.kg(-1).min(-1) in P3-P4, respectively, while NHGU in FLUV averaged 19.7 +/- 2.8 and 26.6 +/- 3.0 mumol.kg(-1).min(-1) (P < 0.05 vs. SAL). Net hepatic carbon retention was greater (P < 0.05) in FLUV than in SAL (17.6 +/- 2.6 vs. 13.9 +/- 2.7 and 23.8 +/- 3.0 vs. 14.4 +/- 3.3 mumol.kg(-1).min(-1) in P3-P4, respectively), and final hepatic glycogen concentrations were 50% greater in FLUV (P < 0.005). Nonhepatic glucose uptake was greater in SAL than in FLUV at 270 min (P < 0.05). Catecholamine concentrations remained basal, and the animals evidenced no distress. Thus fluvoxamine enhanced NHGU and hepatic carbon storage without raising circulating serotonin concentrations or causing stress, suggesting that hepatic-targeted SSRIs might be effective in reducing postprandial hyperglycemia in individuals with diabetes or impaired glucose tolerance.
在高胰岛素-高血糖钳夹实验期间,门静脉内注射5-羟色胺可增强肝脏葡萄糖净摄取量(NHGU),但5-羟色胺会使儿茶酚胺升高并可导致胃肠道不适。我们推测选择性5-羟色胺再摄取抑制剂(SSRI)氟伏沙明可增强NHGU且无副作用。对清醒禁食42小时的犬采用动静脉差和示踪剂([3-(3)H]葡萄糖)技术。实验包括平衡期(-120至-30分钟)、基础期(-30至0分钟)和实验期(EXP;0至270分钟)。在EXP期间,输注生长抑素、基础门静脉内胰岛素4倍量、基础门静脉内胰高血糖素以及外周葡萄糖(使肝脏葡萄糖负荷加倍)。在0至90分钟(P1)门静脉内输注生理盐水(SAL),在氟伏沙明组(n = 8)中,分别在90至150分钟(P2)、150至210分钟(P3)和210至270分钟(P4)以0.5、1和2 μg·kg(-1)·min(-1)门静脉内输注氟伏沙明。SAL组(n = 9)在0至270分钟门静脉内输注生理盐水。SAL组在P3 - P4期的NHGU分别为13.9±1.7和17.0±2.0 μmol·kg(-1)·min(-1),而氟伏沙明组NHGU平均为19.7±2.8和26.6±3.0 μmol·kg(-1)·min(-1)(与SAL组相比,P < 0.05)。氟伏沙明组的肝脏碳净潴留量高于SAL组(P < 0.05)(P3 - P4期分别为17.6±2.6与13.9±2.7以及23.8±3.0与14.4±3.3 μmol·kg(-1)·min(-1)),且氟伏沙明组最终肝脏糖原浓度高50%(P < 0.005)。在270分钟时,SAL组的非肝脏葡萄糖摄取量高于氟伏沙明组(P < 0.05)。儿茶酚胺浓度保持在基础水平,且动物未出现不适。因此,氟伏沙明可增强NHGU和肝脏碳储存,而不升高循环中5-羟色胺浓度或引起应激,提示肝脏靶向性SSRI可能对降低糖尿病患者或糖耐量受损个体的餐后高血糖有效。